Pomerantz Law Firm Investigates Theravance Biopharma for Potential Securities Fraud
Theravance Biopharma (TBPH) announced that its Phase 3 CYPRESS study for ampreloxetine failed to meet its primary endpoint, leading to a 26.33% drop in its stock price. Pomerantz LLP is now investigating potential securities fraud or unlawful business practices by Theravance and its officers/directors.
Tickers: $TBPH
Topics: class action clinical trial failure pharmaceutical industry securities fraud stock price drop